Prevalence of HIV Drug Resistance in Nigeria: Results from a Cross-sectional, Population-based Survey of Nigerian Adults with Unsuppressed Viral Load

Overview

Journal AIDS

Specialty Infectious Diseases

Date 2022 Dec 21

PMID 36541644

Authors

Gambo G Aliyu

Jonathan G Lawton

Andrew B Mitchell

Alashle G Abimiku

Tapdiyel Jelpe

Orji Bassey

David J Riedel

Mahesh Swaminathan

Joy Chih-Wei Chang

Joshua R DeVos

Hetal Patel

Man E Charurat

Kristen A Stafford

Affiliations

Soon will be listed here.

Abstract

Background: HIV drug resistance (HIVDR) surveillance is an important tool to monitor threats to progress towards epidemic control. The characterization of HIVDR in Nigeria at the national level is needed to inform both clinical decisions and population-level HIV policy strategies. This study uses data obtained from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) to describe the prevalence and distribution of HIVDR in Nigeria.

Methods: NAIIS was a cross-sectional, population-based survey of households throughout Nigeria in 2018. NAIIS was designed to provide estimates of HIV prevalence and related health indicators from a nationally representative sample. The study population included participants aged 15-64 years who tested positive for HIV, had a viral load at least 1000 copies/ml, and had available HIV drug resistance genotypes. HIV isolates were genotyped to detect drug resistance mutations. Individual characteristics of study participants associated with HIVDR were identified using a weighted multivariable logistic regression model.

Results: Of 1355 respondents with available HIV genotypes, 293 (19%) had evidence of drug-resistant mutations (DRMs) that conferred resistance to at least one antiretroviral drug. The majority of DRMs observed conferred resistance to NNRTIs (17.6%) and NRTIs (11.2%). HIVDR was associated with being ART-experienced, longer duration on ART, and lower CD4+ count but not sociodemographic characteristics.

Conclusion: The population level DRM prevalence in Nigeria was consistent with what would be expected in a mature HIV treatment landscape. The continued roll out of dolutegravir-anchored regimens should mitigate the impact of NNRTI resistance on population viral load suppression and progress towards epidemic control.

Citing Articles

Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.

Abdullahi A, Kida I, Maina U, Ibrahim A, Mshelia J, Wisso H J Antimicrob Chemother. 2023; 78(8):2000-2007.

PMID: 37367727 PMC: 10393879. DOI: 10.1093/jac/dkad195.

References

Rawizza H, Chaplin B, Meloni S, Darin K, Olaitan O, Scarsi K . Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. PLoS One. 2013; 8(9):e73582. PMC: 3775797. DOI: 10.1371/journal.pone.0073582. View

Gupta R, Jordan M, Sultan B, Hill A, Davis D, Gregson J . Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012; 380(9849):1250-8. PMC: 3790969. DOI: 10.1016/S0140-6736(12)61038-1. View

Boender T, Sigaloff K, McMahon J, Kiertiburanakul S, Jordan M, Barcarolo J . Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. Clin Infect Dis. 2015; 61(9):1453-61. PMC: 4599392. DOI: 10.1093/cid/civ556. View

Crowell T, Kijak G, Sanders-Buell E, OSullivan A, Kokogho A, Parker Z . Transmitted, pre-treatment and acquired antiretroviral drug resistance among men who have sex with men and transgender women living with HIV in Nigeria. Antivir Ther. 2020; 24(8):595-601. PMC: 7304299. DOI: 10.3851/IMP3342. View

Ayitewala A, Kyeyune F, Ainembabazi P, Nabulime E, Drago Kato C, Nankya I . Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda. AIDS Res Ther. 2020; 17(1):2. PMC: 6995161. DOI: 10.1186/s12981-020-0258-7. View

Boender T, Kityo C, Boerma R, Hamers R, Ondoa P, Wellington M . Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J Antimicrob Chemother. 2016; 71(10):2918-27. DOI: 10.1093/jac/dkw218. View

El Bouzidi K, Kemp S, Datir R, Murtala-Ibrahim F, Aliyu A, Kwaghe V . High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment. J Antimicrob Chemother. 2020; 75(6):1575-1579. PMC: 7225870. DOI: 10.1093/jac/dkaa033. View

Hamers R, Schuurman R, Sigaloff K, Wallis C, Kityo C, Siwale M . Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2011; 12(4):307-17. DOI: 10.1016/S1473-3099(11)70255-9. View

Ekong E, Ndembi N, Okonkwo P, Dakum P, Idoko J, Banigbe B . Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria. AIDS Res Ther. 2020; 17(1):7. PMC: 7027291. DOI: 10.1186/s12981-020-0261-z. View

10.

Rousseau C, Birditt B, McKay A, Stoddard J, Lee T, McLaughlin S . Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol Methods. 2006; 136(1-2):118-25. DOI: 10.1016/j.jviromet.2006.04.009. View

11.

Chaplin B, Eisen G, Idoko J, Onwujekwe D, Idigbe E, Adewole I . Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy. AIDS Res Hum Retroviruses. 2010; 27(1):71-80. PMC: 3034099. DOI: 10.1089/aid.2010.0050. View

12.

Miti S, Handema R, Mulenga L, Mwansa J, Abrams E, Frimpong C . Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia. PLoS One. 2020; 15(8):e0236156. PMC: 7430722. DOI: 10.1371/journal.pone.0236156. View

13.

Muri L, Gamell A, Ntamatungiro A, Glass T, Luwanda L, Battegay M . Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern. AIDS. 2016; 31(1):61-70. PMC: 5131685. DOI: 10.1097/QAD.0000000000001273. View

14.

Duong Y, Qiu M, DE A, Jackson K, Dobbs T, Kim A . Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One. 2012; 7(3):e33328. PMC: 3314002. DOI: 10.1371/journal.pone.0033328. View

15.

Etiebet M, Shepherd J, Nowak R, Charurat M, Chang H, Ajayi S . Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. AIDS. 2012; 27(4):553-61. PMC: 6519052. DOI: 10.1097/QAD.0b013e32835b0f59. View

16.

Udeze A, Olaleye D, Odaibo G . Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria. PLoS One. 2020; 15(4):e0231031. PMC: 7141668. DOI: 10.1371/journal.pone.0231031. View

17.

Sigaloff K, Hamers R, Wallis C, Kityo C, Siwale M, Ive P . Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011; 58(1):23-31. DOI: 10.1097/QAI.0b013e318227fc34. View

18.

Crowell T, Danboise B, Parikh A, Esber A, Dear N, Coakley P . Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries. Clin Infect Dis. 2020; 73(7):e2311-e2322. PMC: 8492117. DOI: 10.1093/cid/ciaa1161. View

19.

El Bouzidi K, Datir R, Kwaghe V, Roy S, Frampton D, Breuer J . Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria. J Antimicrob Chemother. 2021; 77(2):474-482. PMC: 8809188. DOI: 10.1093/jac/dkab385. View

20.

Koal T, Burhenne H, Romling R, Svoboda M, Resch K, Kaever V . Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005; 19(21):2995-3001. DOI: 10.1002/rcm.2158. View